Pierre Fabre is responsible for NERLYNX® commercialisation in many countries
Pierre Fabre has always favored a partnership-based approach to research, convinced that complementarity and the sharing of expertise are accelerators of innovation. Puma Biotechnology and Pierre Fabre have entered into an exclusive license agreement under which Pierre Fabre will develop and commercialise NERLYNX® within many countries. Over the years, this agreement has evolved, accessing a true innovation for patients in more and more territories.
Territories indicated in blue are those where Pierre Fabre owns the license of NERLYNX®: